Published in:
01-05-2014 | Neurology and Preclinical Neurological Studies - Short communication
Botulinum toxin in myotonia congenita: it does not help against rigidity and pain
Published in: Journal of Neural Transmission | Issue 5/2014
Login to get accessAbstract
Botulinum toxin (BT) is a potent local muscle relaxant with analgetic properties. Myotonia congenita (MC) is a genetic disorder producing muscle rigidity and pain. BT injected into the trapezius produced mild paresis, but no effect on rigidity and pain. There were no signs of systemic effects. Lack of BT efficacy on MC rigidity confirms its origin from muscle membrane dysfunction rather than from inappropriate neuromuscular activation. Lack of BT efficacy on pain could be caused by lack of anti-rigidity effect. It could also be due to separate non-muscular pain mechanisms unresponsive to BT.